ZGJTSXF administration could ameliorate DCM mice by remodeling gut microbiota structure, reducing serum TMAO generation and suppressing TMAO/PERK/FoxO1 signaling pathway. The gene discussed is FOXO1; the disease is familial dilated cardiomyopathy.